Autonomix Medical Reports Going Concern, Nasdaq Delisting Threat, and Material Internal Control Weaknesses
AMIX has more than doubled off its 52-week low of $0.2.
Summary
Autonomix Medical's 10-K reveals a going concern warning, a Nasdaq delisting threat, and material weaknesses in internal controls, alongside a short cash runway and significant share dilution.
Key Events · Corporate Governance and Compliance · AMIX
-
Going Concern Warning Issued
The company's auditor and management have issued a going concern warning, citing an accumulated deficit of $67.1 million, negative operating cash flows of $12.3 million, and a cash runway only into Q4 2026.
-
Nasdaq Delisting Threat
Autonomix Medical received a deficiency letter from Nasdaq on January 14, 2026, for failing to maintain a minimum $1.00 bid price. The company has until July 13, 2026, to regain compliance or face potential delisting.
-
Material Weaknesses in Internal Controls
Management concluded that internal controls over financial reporting were ineffective as of March 31, 2026, due to a lack of segregation of duties, general technology controls, and financial statement reporting deficiencies.
-
Significant Share Dilution
Shares outstanding increased from 2,497,033 to 11,409,344 during the fiscal year ended March 31, 2026, representing a substantial increase of approximately 350% due to recent equity offerings and warrant exercises.
Analysis · AMIX · Industrial Applications And Services
Autonomix Medical's annual report highlights severe financial distress, including a going concern warning from its auditor and management, indicating insufficient cash to fund operations beyond Q4 2026. The company also faces a Nasdaq delisting threat due to its stock price falling below the $1.00 minimum bid requirement, with a compliance deadline of July 13, 2026. Furthermore, management identified material weaknesses in internal controls over financial reporting, and the financial statements reflect a correction of a previously issued error. While the company is advancing its medical device technology and has raised capital, the significant dilution from recent offerings (shares outstanding increased by ~350% in one year) and the operational challenges in clinical trials underscore the precarious situation.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 45.2% of the 299 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.26%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMIX was trading at $0.42 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.20 to $2.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.